Le, Dung T.

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersGenetic factors in colorectal cancer

Cited by 9,377

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 6,645

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine

Cancer Genomics and DiagnosticsPrenatal Screening and Diagnostics

Cited by 5,067

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer

André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine

Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies

Cited by 3,099

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery

Cancer Immunotherapy and Biomarkersinterferon and immune responses

Cited by 1,337

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology

Lung Cancer Research StudiesCancer Immunotherapy and Biomarkers

Cited by 1,244

Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164

Le, D. T., Kim, T. W., Van Cutsem, E., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B., Kavan, P., Yoshino, T., et al. (2020) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 1,005

Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes –Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

Le, D. T., Wang-Gillam, A., Picozzi, V., Greten, T. F., Crocenzi, T., Springett, G., Morse, M., Zeh, H., Cohen, D., Fine, R. L., et al. (2015) · Journal of Clinical Oncology

Immunotherapy and Immune ResponsesPancreatic and Hepatic Oncology Research

Cited by 611

Regulatory T-cell Modulation Using Cyclophosphamide in Vaccine Approaches: A Current Perspective

Le, D. T., & Jaffee, E. M. (2012) · Cancer Research

T-cell and B-cell ImmunologyImmunotherapy and Immune Responses

Cited by 240

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma

Hopkins, A. C., Yarchoan, M., Durham, J. N., Yusko, E. C., Rytlewski, J. A., Robins, H. S., Laheru, D. A., Le, D. T., Lutz, E. R., & Jaffee, E. M. (2018) · JCI Insight

Cancer Immunotherapy and BiomarkersPancreatic and Hepatic Oncology Research

Cited by 233

Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation

Braaten, T. J., Brahmer, J. R., Forde, P. M., Le, D., Lipson, E. J., Naidoo, J., Schollenberger, M., Zheng, L., Bingham, C. O., Shah, A. A., et al. (2020) · Annals of the Rheumatic Diseases

Cancer Immunotherapy and BiomarkersRheumatoid Arthritis Research and Therapies

Cited by 230

Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): An open-label, randomised, phase 3 trial

Andre, T., Amonkar, M., Norquist, J. M., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D., Garcia-Carbonero, R., et al. (2021) · The Lancet Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 209

Pembrolizumab versus chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 Study

Andre, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 194

KEYNOTE-177: Phase III randomized study of pembrolizumab versus chemotherapy for microsatellite instability-high advanced colorectal cancer

Shiu, K.-K., Andre, T., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C. J. A., Smith, D. M., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2021) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancer

Cited by 59

Cell-free DNA Predicts Prolonged Response to Multi-agent Chemotherapy in Pancreatic Ductal Adenocarcinoma

Christenson, E. S., Lim, S. J., Durham, J., De Jesus-Acosta, A., Bever, K., Laheru, D., Ryan, A., Agarwal, P., Scharpf, R. B., Le, D. T., et al. (2022) · Cancer Research Communications

Pancreatic and Hepatic Oncology ResearchCancer Genomics and Diagnostics

Cited by 12

Phase 3, open-label, randomized study of first-line pembrolizumab (pembro) vs. investigator-choice chemotherapy for mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal carcinoma (mCRC): KEYNOTE-177

Diaz, L. A., Le, D. T., Yoshino, T., Andre, T., Bendell, J. C., Koshiji, M., Zhang, Y., Kang, S. P., Lam, B., & Jaeger, D. (2017) · Journal of Clinical Oncology

Colorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers

Cited by 11

Gemcitabine, Docetaxel, Capecitabine, Cisplatin, Irinotecan as First-line Treatment for Metastatic Pancreatic Cancer

Wilbur, H. C., Durham, J. N., Lim, S. J., Purtell, K., Bever, K. M., Laheru, D. A., De Jesus-Acosta, A., Azad, N. S., Wilt, B., Diaz, L. A., et al. (2023) · Cancer Research Communications

Pancreatic and Hepatic Oncology ResearchCancer Treatment and Pharmacology

Cited by 9